Comparing the effectiveness of deucravacitinib and apremilast for plaque psoriasis in adults in Japan
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan
This study is testing whether a new medication called deucravacitinib works better than apremilast for adults with plaque psoriasis in Japan.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | deucravacitinib |
| Locations | 2 sites (Minato-ku, Tokyo and 1 other locations) |
| Trial ID | NCT06382987 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the real-world effectiveness of deucravacitinib compared to apremilast in adults diagnosed with plaque psoriasis in Japan. Participants will be adults aged 18 and older who are newly starting treatment with either medication, as reported by their physicians. The study will gather data on treatment outcomes and patient experiences to assess the comparative effectiveness of these two therapies.
Who should consider this trial
Good fit: Ideal candidates are Japanese adults aged 18 and older with a physician-confirmed diagnosis of plaque psoriasis who are beginning treatment with either deucravacitinib or apremilast.
Not a fit: Patients currently involved in other interventional clinical trials or those with prior treatment experience with the medications being studied may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into which treatment is more effective for managing plaque psoriasis in the Japanese population.
How similar studies have performed: While this study focuses on a specific population and treatment comparison, similar observational studies have shown promise in evaluating real-world treatment effectiveness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Japanese adult participants aged 18 years old or older * Physician-reported diagnosis of plaque psoriasis * Newly initiating deucravacitinib or apremilast according to the label * Participants who have signed informed consent Exclusion Criteria: * Participants currently participating in or planning to participate in an interventional clinical trial * Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264) * Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)
Where this trial is running
Minato-ku, Tokyo and 1 other locations
- Mebix. Inc. — Minato-ku, Tokyo, Japan (Recruiting)
- Fukuoka University Hospital — Fukuoka, Japan (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.